Eric Petitclerc, PhD. D.

**** *** *** ********

L’Ancienne-Lorette, QC

G2E 5R6

Telephone: 418-***-**** (Home)

Email address: acrw2t@r.postjobfree.com

Profile.

I have been a Scientist/Project Manager in molecular pharmacology and in transfusion medicine for 15 years. I have lead research teams in molecular pharmacology, immunology of autoimmune diseases and oncology. During my career, I directed successful undergrad and grad students. I also taught to lab technicians, grad and undergrad students. I was also responsible of the approbation and the management of clinical studies implementation. I have a small experience in non- pharmaceutical sales. I am bilingual.

Work experience.

12/2012 – 02/2015 Scientific adviser, Hôtel-Dieu de Lévis Research center, Lévis.

• Approval of the institutional feasibility of clinical research projects.

• Coordination with the research ethics committee.

• Direct interactions with the pharmaceutical companies for clinicians/administrative requests.

• Drafting and editing of clinical research projects, renewals, amendments.

• Drafting and updating of documents related to policies related to research projects, scientific integrity, discipline Committee, SOPs, etc.

02/2010 – 11/2012 Scientist, R&D dept., Héma-Québec, Québec.

• Advanced scientific research in molecular pharmacology (development of substitutes for IVIG).

• Training of Héma-Québec staff and province hospital laboratory technologists (Science behind laboratory tests).

• Support the departments of production, validation of blood products conformity.

• Equipment Validation molecular typing of platelets and high-speed technology transfer to clinical laboratories.

• Teaching 3 academic cycles, molecular pharmacology (Laval University, Faculty of Medicine). 07/2006 – 01/2010 Associate professor, dept. medicine, Université Laval. CHUQ, unité des biomatériaux et biotechnologies, Hop. St-François d’Assise. 07/2000 – 06/2006 Adjunct professor, dept. medicine, Université Laval Centre de recherche en cancérologie de l’Hôtel-Dieu de Québec (2000-2002) and Unité des biomatériaux, Hop. St-François d’Assise, (2002-2006).

• Advanced scientific research in molecular pharmacology (Tumor biology, tumor metabolism).

• Teaching to university students, tumor biology and pharmacology.

• Analysis and correction of master's and doctoral thesis. Participation in doctoral defense juries.

• Writing and validation research protocols, patent applications.

• Negotiation with pharmaceutical and biotechnology companies for research contracts.

• Writing, in English and French, large research programs to obtain grants and scientific articles.

• Oral presentations with audiences of all scientific levels. Postdoctoral fellowships

08/1997 – 05/2000 Lab. Dr Peter C. Brooks, U. Southern California, Los Angeles, CA, USA 06/1995 – 07/1997 Lab. Dr David A. Cheresh, The Scripps Research Institute, San Diego, CA, USA Education.

1995 Ph.D., Pharmacology. Université Laval, dept. experimental medicine

“Modulation of the vascular tone by the resident leukocytes of the vascular wall.” Lab. Dr François Marceau

1992 M.Sc., Pharmacology. Université Laval, dept. experimental medicine

“Vascular responses to interleukin-1.”

Labo. Dr François Marceau

1990 B.Sc. Microbiology. Université Laval, dept. biochemistry & microbiology Skills.

• Scientific project manager. Managing a multidisciplinary team.

• Basic and applied research in molecular pharmacology, immunology and oncology.

• Teaching to undergrad and grad students, molecular pharmacology, haematology.

• Teaching to Quebec hospitals’ laboratory technicians in basic immunology.

• Writing and editing of research protocols, research projects and patents.

• Negotiation with pharmaceutical and biotechnological companies for research contracts.

• Writing of research grants, both in French and English. scientific reports, articles and abstracts.

• Management of scientific multidisciplinary teams.

• Fluent in French and English.

Achievements.

• 21 published articles as a principal investigator in the academia, 43 overall.

• Management of a research laboratory with research assistants, postdocs and grad students. Administrative work related to the research centre activities.

• Creation of seven classes for undergrad and grad students in various fields of pharmacology.

• Writing and editing of a patent related to the discovery of a monoclonal antibody with antitumor activity.

Consulting activities.

Lab-Bel inc. Shawinigan, December 2008 – 2010.

Gestion Valeo s.e.c. (affiliated to l’Université du Québec à Montréal). May 2004 - 2010. Virexx Inc. Validation of the antiangiogenic capacity of selected drugs. 02/02003 – 02/06/2004. IMOTEP inc. Québec. 2002 – 2004.

Merck Barcelona. Barcelona, Spain. 2001 – 2002.

Guest speaker.

• University of Southern California, Dept. Biochemistry and Molecular Biology Potential use of Aryl ChloroEthyl Ureas (ACEUs) in colon cancers. April 16, 2007

• University of Montréal, Dept. of medicine

Caractérisation de l’activité anti-tumorale et anti-angiogénique d’une nouvelle classe d’agents anti-cancéreux, les alkylants "doux" de type aryl-chloroéthyl urées (ACEU). October 27, 2004

• Alliance canadienne pour la recherche sur le cancer (IRSC-IRC, INCC, ACAPC, Santé Canada), Crucial Cancer Research Planning, Young investigator, Focus group

March 21-22 2004, Toronto

• Université Laval. Salon des carrières.

From postdoc to assistant professor in the academia. February 21 2001

• University of Barcelona. Faculty de biology, dept. of cellular biology The role of extracellular matrix remodelling in angiogenesis and tumour growth. August 10, 2001

Appendix

Publications (43 articles since 1989, last 5 years shown). 43. Fortin, S, Wei, L, Moreau, E, Lacroix, J, Cote, MF, Petitclerc, E, Kotra, LP, C.-Gaudreault, R. Design, synthesis, biological evaluation, and structure-activity relationships of substituted phenyl 4-(2-oxoimidazolidin-1- yl)benzenesulfonates as new tubulin inhibitors mimicking combretastatin A-4. J Med Chem 54(13): 4559-4580. 2011

42. Fortin, S, Wei, L, Moreau, E, Lacroix, J, Cote, MF, Petitclerc, E, Kotra, LP, Gaudreault, RC. Substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonamides as antimitotics. Antiproliferative, antiangiogenic and antitumoral activity, and quantitative structure-activity relationships. Eur J Med Chem 46(11): 5327-5342. 2011. 41. Faucher, L, Guay-Begin, AA, Lagueux, J, Cote, MF, Petitclerc, E, Fortin, MA. Ultra-small gadolinium oxide nanoparticles to image brain cancer cells in vivo with MRI. Contrast Media Mol Imaging 6(4): 209-218. 2011 40. Patenaude, A, Fortin, JS, Deschenes, R, Cote, MF, Lacroix, J, R, CG, Petitclerc, E. Chloroethyl urea derivatives block tumour growth and thioredoxin-1 nuclear translocation. Can J Physiol Pharmacol 88(11): 1102-1114. 2010.

39. Fortin, J.S., Patenaude, A., Deschesnes, R., Nadeau, P., Côté, M.F-. C.-Gaudreault, R., Petitclerc, E. ASK1-p38 Pathway is Important for Apoptosis Induced by Microtubule-Targeting Aryl Chloroethylureas. J Pharm Pharm Sci 13(2): 175-190. 2010.

38. Fortin, S, Wei, L, Moreau, E, Labrie, P, Petitclerc, E, Kotra, LP, C.-Gaudreault, R. Mechanism of action of N- phenyl-N'-(2-chloroethyl)ureas in the colchicine-binding site at the interface between alpha- and beta-tubulin. Bioorg Med Chem 17(10): 3690-3697. 2009.

37. Vallieres, K, Petitclerc, E, Laroche, G. On the ability of imatinib mesylate to inhibit smooth muscle cell proliferation without delaying endothelialization: an in vitro study. Vascul Pharmacol 51(1): 50-56. 2009. 36. Koumbadinga, GA, Petitclerc, E, Bouthillier, J, Adam, A, Marceau, F. Receptor tyrosine kinases as mediators of injury-induced bradykinin B1 receptor expression in rabbit aortic smooth muscle. Eur J Pharmacol 606(1-3): 233-239. 2009.

35. Brousseau, C, Morissette, G, Fortin, JP, Marceau, F, Petitclerc, E. Tumor cells expressing tissue factor influence the migration of smooth muscle cells in a catalytic activity-dependent way. Can J Physiol Pharmacol 87(9): 694- 701. 2009,

34. Fortin, J.S., Coté, M.F., Lacroix, J., Desjardins, M., Petitclerc, E., C-Gaudreault, R. Selective alkylation of beta- tubulin and trx-1 by structurally related subsets of aryl chloroethylureas leading to either anti-microtubules or redox modulating agents. Bioorg. Med. Chem. 16: 7277-7290. 2008. 33. Fortin, J.S., Coté, M.F., Lacroix, J., Petitclerc, E., C.-Gaudreault, R.. Aromatic 2-chloroethyl urea derivatives and bioisosteres. Part 2: Cytocidal activity and effects on the nuclear translocation of thioredoxin-1, and the cell cycle progression. Bioorg Med Chem 16: 7477-88. 2008 32. Fortin, J.S., Coté, M.F., Lacroix, J., Patenaude, A., Petitclerc, E., C.-Gaudreault, R.. Cycloalkyl-substituted aryl chloroethylureas inhibiting cell cycle progression in G0/G1 phase and thioredoxin-1 nuclear translocation. Bioorg Med Chem Lett 18: 3526-31. 2008.

31. Fortin, J.S. Lacroix, J., Desjardins, M., Patenaude, A., Petitclerc, E., C.-Gaudreault, R. Alkylation potency and protein specificity of aromatic urea derivatives and bioisosteres as potential irreversible antagonists of the colchicine-binding site. Bioorg. Med. Chem. 15, 4456-4469. 2007. 30. Vallières, K., Petitclerc, E., Laroche, G. Covalent Grafting of Fibronectin onto Plasma-Treated PTFE: Influence of the Conjugation Strategy on Fibronectin Biological Activity. Macromol. Biosci. 7, 738–745. 2007. 29. Patenaude, A., Deschesnes, R.G., Rousseau, J.L., Petitclerc, E., Lacroix J., Cote M.-F., C.-Gaudreault, R. New Soft Alkylating Agents with Enhanced Cytotoxicity against Cancer Cells Resistant to Chemotherapeutics and Hypoxia. Cancer Res. 67, 2306-2316. 2007.

28. Deschesnes, R.G., Patenaude, A., Rousseau, J.L., Fortin, J.S., Ricard, C., Cote, M.-F., Huot, J., C.-Gaudreault, R., Petitclerc E. Microtubule-destabilizing agents induce focal adhesion structure disorganization and anoikis in cancer cells. J. Pharmacol. Exp. Ther. 320, 853-864. 2007. Abstracts (36 since 1989, last 5 years shown).

36. Fortin, M.A., Guay-Bégin,A.-A., Faucher, L., Éric Petitclerc. Visualizing tumor growth with MRI by using positive contrast agents. 27ème conférence annuel le de la société canadienne des biomatér iaux. Québec. 20-23 mai 2009.

35. Fortin, J.S., Patenaude, A., Côté, M.-F., Lacroix, J., Petitclerc, E., C.-Gaudreault, R., Design of new antineoplastics alkylating the thioredoxin-1 (Trx); a key protein of the cellular redox status involved in tumor progression (10th Canadian Society for Pharmaceutical Sciences (CSPS) Annual Meeting, 64th Association of Faculties of Pharmacy of Canada (AFPC) Annual Meeting), Published: From Bench to Market, Montréal May 30 – June 2, Symposium 2007.

34. Fortin, J.S., Lacroix, J., Desjardins, M., Patenaude, A., Petitclerc, E., C.-Gaudreault, R., Evaluation of alkylation potency of aromatic urea derivatives and bioisosteres of -tubulin as potential antineoplastic agents (10th Canadian Society for Pharmaceutical Sciences (CSPS) Annual Meeting, 64th Association of Faculties of Pharmacy of Canada (AFPC) Annual Meeting), Published: From Bench to Market, Montréal May 30 – June 2, Symposium 2007.

33. Fortin J.S., Patenaude, A., Côté, M.-F., Lacroix, J., Petitclerc, E., C.-Gaudreault, R., Préparation de nouveaux agents anticancéreux ciblant la thiorédoxine-1; une protéine importante pour l’homéostasie Redox et la prolifération cellulaire (communication # 738, poster). 75e Congrès de l’Acfas, Trois-Rivières, 7 au 11 mai 2007.

32. Fortin J.S., Côté, M.-F., Patenaude, A., Petitclerc, E., C.-Gaudreault, R. Préparation de nouveaux agents anticancéreux inhibiteurs de la thiorédoxine; une protéine clé de l’homéostasie Redox de la cellule.

(communication # 732, poster). 75e Congrès de l’Acfas, Trois-Rivières, 7 au 11 mai 2007. 31. Patenaude, A., Fortin, J., Petitclerc, E., Deschesne, R. G., Côté, M.F., Lacroix, J., C.-Gaudreault, R., New Aryl Chloroethylureas Derivatives that Inhibit Cancer Cell Growth Target Thioredoxin-1 and Abolish its Nuclear Translocation. The American Association for Cancer Research Annual Meeting, April 14-18, 2007, Los Angeles, CA, USA.

Book chapters.

2. Petitclerc, E., von Schalscha, T.L., Brooks, P.C. The chimeric human/mouse model of angiogenesis. Methods in Molecular Biology. Developmental Biology Protocols, Vol. III. 137: 213-221, 1999. 1. Petitclerc, E., Brooks, P.C. The chick embryo metastasis model. Metastasis Research Protocols, Methods in Molecular Medicine series. Brooks SA and Schumacher U (eds). Humana Press. Volume II, 173-188, 2001.

Academic teaching.

BMO-66391: Fondements cellulaires et moléculaires du cancer. 3 crédits Subject: Cancer cells interactions with their microenvironment. PHC-61897: Théorie des récepteurs. 2 crédits

Subject 1: Serine/threonine kinase receptors family (TGF-b receptors). PHC-11234: Introduction à la pharmacologie. 1 crédit Subjects: 1. Drug classification, 2. Food-drugs interactions. PHC-18318: Éléments de pharmacologie. 1 crédit

Subjects: 1. Narcotic analgesic.

2. Drugs for the treatment of gut diseases.

PHC-16486: Principes et problèmes de pharmacologie. 1 crédit Subjects: 1. Anti-coagulants.

2. The extracellular matrix as a therapeutic tool. 3. Introduction to biomaterials.

BCX-66492: Angiogenèse, Vasculogenèse, Lymphangiogenèse. 2 crédits Subject: Extracellular matrices, intégrins, angiostatin, endostatin, experimental models. GML-66128: Biomatériaux et organes artificiels. 2 crédits Subjects: The immune and inflammatory responses.

Theses evaluations, studentship and fellowship reviewer board.

• The Cancer Research Sociey, Inc. Postdoctoral fellowship evaluation. 2007 and 2008.

• Fonds de la recherche en santé du Québec (FRSQ). M.Sc. studentship evaluation. 2008.

• Medical student entry exam, “appréciation par simulation” (APS, 2003-2008)

• 10 M.Sc. theses and 3 Ph.D. theses (since 2002). Grad and postdoctoral fellow supervisions (since 2000). 3 postdocs, 2 Ph.D. Students, 5 M.Sc. students 8 summer students. Peer-reviewed grants.

Canadian Institutes for Health Research (CIHR)

Committee: Pharmaceutical Sciences.

Aryl 2-chloroethylureas as thioredoxin and cellular redox homeostasis inhibitors: Structure-activity relationships and mechanisms of anticancer activity. March 2008 – February 2013

$125,000/year. Co-PI: C.-Gaudreault, René

Canadian Institutes for Health Research (CIHR)

Committee: Pharmaceutical Sciences.

Pharmacological study and pharmacomodulation of 1-aryl-3(2-chloroethyl)ureas, a new class of antimitotic alkylating agents.

March 2006 - February 2011

$124,281/year. Co-PI: C.-Gaudreault, René

Société de recherche sur le cancer (La)

Inflammatory genes as virulence factors in tumorigenic cell lines. September 2004 - September 2006

60,000 $/year, 2 years. PI. Collaborator: Dr. François Marceau Canadian Institutes for Health Research (CIHR)

Committee: Cancer B.

Modulation of the cellular redox status by chloroethyl ureas in the design of new strategies and drugs for cancer chemotherapy.

March 2004 – 28 February 2005

90,815 $/year. Co-PI: C.-Gaudreault, René

Canadian Institutes for Health Research (CIHR)

Committee: Cancer B

The Function of Soft Alkylating Agents in Tumor Growth and Angiogenesis March 1, 2002 - March, 2005

114,646 $/ year. Co-PI: C.-Gaudreault, René

Société de recherche sur le cancer (La)

Tumorigenic cell lines affect host vascular smooth muscle. September 2002- September 2004

54,000 $/year, 2 ans. Co-PI: Dr. François Marceau. Fondation des maladies de l’oeil

Étude de gènes candidats conférant au mélanome uvéal ses propriétés tumorigènes et métastatiques. May 2002 - May 2005

25 000$/year, 3 years. Co-PI: Sylvain Guérin et Christian Salesse Société de recherche sur le cancer (La)

The role of tissue transglutaminases in tumor growth and angiogenesis. September 2001 – August 31 2003

60 000 $/year, 2 years. PI.

Peer-reviewed grants (continued).

Merck Barcelona (Spain), affiliate of Merck KGA (Essen, Germany) Anti-angiogenic effects of the EMD 72000 antibody. June 2002 – December 2002

15 000 $. PI

Alliance canadienne pour la recherche sur le cancer du sein (IDEA grants) The role of transglutaminases in breast tumor growth and survival. April 1, 2001 - March 31, 2002

35 000 $ for 1 year. PI

Honors and Scholarships.

2008 Scientific merit, Chercheur Senior, Fonds de recherche en santé du Québec 2005 Scholarship, Junior II, Fonds de recherche en santé du Québec 2004 Scientific merit, Junior II, Fonds de recherche en santé du Québec 2003 Poster award ($500), Soc. Can. des sciences pharmaceutiques, 6e symposium, Montréal, QC. 2003 Poster award, Journées d’ophtalmologie de l’Université Laval 2002 Poster award ($500), “Journée de la recherche”, Faculté de pharmacie, U. Laval. (avril). 2002 Scholarship, Junior I, Fonds de recherche en santé du Québec 2000 Poster award ($1,000), BD Pharmingen, Jeune investigateur, réunion AACR, San Francisco 1998 Postdoctoral fellowship, Fonds de recherche en santé du Québec 1995 Postdoctoral fellowship,, Conseil de recherches médicales du Canada (CRM) 1993 Doctoral fellowship, Fonds pour la formation de chercheur et l’aide à la recherche, (Ph.D.) 1992 Doctoral fellowship, Fondation Dr Georges Phénix, (Ph.D.) 1990 M.Sc. studentship, Fonds pour la formation de chercheur et l’aide à la recherche, (M.Sc.) Patents.

Famille de peptides capables d’inhiber l’activation de la molécule C3 du complément. Provisional patent. November 2012.

Inventors: Eric Petitclerc, Eric Aubin

Method and Composition for Angiogenesis Inhibition United States Patent and Trademark Office (USPTO) #60/114,877 January 6, 1999, Worldwide License

Inventors: Peter C. Brooks, Eric Petitclerc and Jingsong Xu Affiliation.

Member, Réseau-Vision, acknowledged by the Fonds de recherche en santé du Québec. 2002-2007

Chairman, oral presentation session,

Club de recherches cliniques du Québec (CRCQ) meeting, September 23-25, 2004

Contact this candidate